Zacks Investment Research downgraded shares of BRAINSWAY LTD/S (NASDAQ:BWAY) from a buy rating to a hold rating in a report issued on Tuesday morning, Zacks.com reports.
According to Zacks, “BrainsWay Ltd. is a commercial stage medical device company. It is focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation technology for the treatment of major depressive disorder and obsessive-compulsive disorder. BrainsWay Ltd. is based in Jerusalem, Israel. “
BWAY has been the topic of several other reports. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research note on Monday, May 13th. They issued an overweight rating and a $21.00 price target on the stock. Oppenheimer boosted their price target on Novavax from $1.25 to $25.00 in a research note on Monday, May 13th. CIBC boosted their price target on NorthWest Health Prop Real Est Inv Trust from C$11.75 to C$12.00 in a research note on Monday, May 13th. Raymond James reissued a neutral rating and issued a $35.00 price target on shares of Stantec in a research note on Monday, May 13th. Finally, LADENBURG THALM/SH SH lowered PennantPark Investment from a buy rating to a neutral rating in a research note on Monday, May 13th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $15.80.
Shares of BWAY opened at $10.15 on Tuesday. BRAINSWAY LTD/S has a 52-week low of $8.00 and a 52-week high of $12.39. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.32. The firm has a 50 day simple moving average of $9.94.
BRAINSWAY LTD/S (NASDAQ:BWAY) last issued its quarterly earnings results on Wednesday, May 29th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. The business had revenue of $5.18 million during the quarter, compared to analyst estimates of $5.00 million. Equities analysts predict that BRAINSWAY LTD/S will post -0.43 earnings per share for the current year.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Article: Understanding each part of a balance sheet
Get a free copy of the Zacks research report on BRAINSWAY LTD/S (BWAY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.